Davita Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Global X Lithium & Battery Tech ETF trades at $69.02 (market cap $1.49B). The key difference: Davita Inc is far larger — about 7.6× Global X Lithium & Battery Tech ETF's market cap, and Davita Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| DVA | LIT | |
|---|---|---|
Market Cap | $11.28B | $1.49B |
Volume | 650,294 | 67,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $240.96 | $91.62 |
52-Week Low | $103.87 | $53.92 |
Typical Hold Time | 113 Days | 56 Days |
Enterprise Value | $24.00B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
LIT trades at $69.51, down 2.2% today amid mixed technical signals with a bullish overall rating but bearish moving averages and oscillators. The ETF's recent performance reflects volatility in lithium markets, with short interest dropping 53.1% in September. Key technical levels show support at $70 and resistance at $72. Recent news highlights ongoing EV sector growth with China targeting 30% NEV fleet by 2030, providing long-term tailwinds.
LIT offers exposure to the expanding battery technology sector with catalysts from EV adoption and energy storage demand. However, risks include lithium price volatility and Chinese export controls. The ETF's momentum is supported by semiconductor and AI-driven battery demand, though current technical indicators suggest near-term consolidation may precede further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →